|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
ADC, mainly ADC<sub>oscillating</sub> , increased in the group of nodules with intermediate malignancy (ADC<sub>pulsed</sub> : 0.75 ± 0.25 × 10<sup>-3</sup> mm<sup>2</sup> /s vs. 0.64 ± 0.07 × 10<sup>-3</sup> mm<sup>2</sup> /s in benign nodules, P = 0.025; ADC<sub>oscillating</sub> : 0.81 ± 0.20 × 10<sup>-3</sup> mm<sup>2</sup> /s vs. 0.65 ± 0.13 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.0008) and ADC<sub>pulsed</sub> decreased in the group of progressed hepatocellular carcinomas (ADC<sub>pulsed</sub> : 0.60 ± 0.08 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.042; ADC<sub>oscillating</sub> : 0.68 ± 0.08 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.1).
|
31507025 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, statistically significant differences were found between the noncancer and cancer groups in T2 values and ADC values (diff TEs) (P = 0.000).
|
31218387 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In univariate analysis, lower ADC, axial diffusivity, and radial diffusivity were associated with malignancy (OR = 0.37-0.42 per 1-SD increase, p < 0.001 for each), as was higher FA (OR = 1.45, p = 0.007).
|
31484577 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The 10th percentile ADC obtained from ultrahigh b-value DWI performed better for differentiating TZ cancer from BPH.
|
30475249 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
To determine if PSAD, PSADtz, and ADC values improve the accuracy of PI-RADS v2 and identify men whose concurrent systematic biopsy detects clinically significant cancer on areas without mpMRI visible lesions.
|
31136112 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The estimate of Ln probability of malignancy (low, moderate, high) was based on nodal size, border contour and signal intensity and comparison between ADC value of the Ln's belonging to the three different classifications were performed.
|
28497665 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that in future studies of PI-RADSv2 upgraded category 4 and category 4 based on markedly low ADC value should be reported separately to generate a database for meta-analysis of cancer rates.
|
29362152 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
We performed a logistic regression analysis to examine each institute's weighting of T2w, ADC and K<sup>trans</sup> intensity maps in the delineation of the cancer.
|
29731160 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The payload was successfully conjugated to trastuzumab and the resulting ADC exhibited potent activity against a HER2-expressing human cancer cell line in vitro.
|
28188066 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
At multivariable analysis of entropy in combination with all other ADC histogram and conventional MRI features, entropy was the only significant independent predictor of malignancy (p = 0.004).
|
27900458 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
ADC<sub>min</sub> was measured, by two independent, blinded readers, using a region of interest (ROI) of 5-10 mm<sup>2</sup> at the area of lowest ADC value within a cancer, while ADC<sub>mean</sub> was measured using an ROI covering more than half of a cancer.
|
26823024 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
For transition zone, significantly increased cancer detection was shown for location (anterior 0.63±0.15 vs. mid/posterior 0.31±0.14; p=0.0048), border (pseudo-capsule 0.32±0.14 vs. ill-defined 0.61±0.15; p=0.0092), and ADC (mild 0.35±0.12 vs marked restriction 0.68±0.17; p=0.0057).
|
28987685 |
2017 |